KRT8 and cancer: In these primary non-cancerous cells, ML-60218 inhibited pre-tRNATyr by 40%, comparable to the matched cancer cells (36% inhibition), but had minimal effect on DR2 Alu, NANOG, CK8 or CK14 expression (Figure 6C).